Whole Cell Cholera Vaccine is used to prevent Cholera.
The factors that fuel the growth of the global whole cell cholera vaccine (recombinant B-subunit) market are rising incidence of cholera among people in endemic regions along with a lack of sanitation and hygiene in certain countries.

The global Whole Cell Cholera Vaccine market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Whole Cell Cholera Vaccine volume and value at global level, regional level and company level. From a global perspective, this report represents overall Whole Cell Cholera Vaccine market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Whole Cell Cholera Vaccine in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Whole Cell Cholera Vaccine manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
SBL Vaccine
PaxVax
Valneva SE
GlaxoSmithKline
Johnson and Johnson
Merck
Pfizer
Sanofi Pasteur
AstraZeneca(Medimmune, LLC.)
Serum Institute of India

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
For Adults
For Children

Segment by Application
Clinical Research Institutes
Hospital
Surgical Centers
Others